Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceuticals Not Likely To Be A Target Of Republicans In Coming Congress, Hill Watchers Say

This article was originally published in The Pink Sheet Daily

Executive Summary

Some issues - such as drug importation or rebates for Medicare/Medicaid dual eligibles - could surface. GOP could make "surgical strikes" on health reform law, including the Independent Payment Advisory Board, if overall repeal of reform law fails.

You may also be interested in...



Mandatory Part D Drug Rebates Proposed By Deficit Panel Leaders; Stronger IPAB Also On The Table

The co-chairs of the bipartisan National Commission on Fiscal Responsibility and Reform issued a cost-savings proposal for the government, including Medicare, on Nov. 10, but it will need approval by 14 of 18 members before going to the president.

For PhRMA, There Is Good News And Bad News In The Mid-Term Elections

The anti-government intervention sentiment coming to Congress in January with the newly elected Republicans presents a tactical challenge to lobbying efforts by the Pharmaceutical Research and Manufacturers of America.

PhRMA Deal Remains Intact As Senate Majority Leaders Vote Against Drug Importation

The $80 billion deal the Rx industry struck as part of health care reform lives to see another day as drug importation fails on the Senate floor.

Topics

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel